Learn More
PURPOSE Irinotecan, a topoisomerase I inhibitor, is an effective agent for non-small-cell lung cancer (NSCLC). To determine the efficacy and toxicity of irinotecan and carboplatin, we conducted a phase II study in 61 patients with advanced NSCLC. METHODS Every 4 weeks, the patients received irinotecan 50 mg/m2 (days 1, 8 and 15) and carboplatin (day 1)(More)
The function of maintaining posture during temporary unbalance caused by experimental vestibular asymmetry was studied. Galvanic stimulation to the vestibular nerve causing body deviation to the stimulated ear was given to 31 normal subjects and 16 patients with peripheral vestibular disorders. The velocity of spontaneous body sway and that during body(More)
UNLABELLED BACKGROUND Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with chronic myelogenous leukemia and gastrointestinal stromal tumor. Although imatinib-associated interstitial lung disease is uncommon, a few cases have been reported so far. However, in all these cases interstitial lung disease(More)
  • 1